Constant Drug Dose Leading Long-Term Non-Progressor for HIV-Infected Patients with RTI and PI

This paper proposes a therapy that uses a constant dosage of Reverse Transcription Inhibitor (RTI) and Protease Inhibitor (PI) to help an HIV-infected patient achieve Long-Term Non-Progressor (LTNP) status. Based on the analysis of the Cytotoxic T Lymphocyte precursor (CTLp) concentration at the equilibrium point and the bifurcation of the equilibrium points, we found that therapy with a drug whose efficacy was below a certain level produced a higher CTLp concentration at the equilibrium point. We found that it is possible for a less-than-full constant dosage treatment to induce LTNP status. In fact, the treatment with an efficacy less than that of a full treatment proved to be more efficient when considering controllability.